Authors:
Vahdat, L
Papadopoulos, K
Lange, D
Leuin, S
Kaufman, E
Donovan, D
Frederick, D
Bagiella, E
Tiersten, A
Nichols, G
Garrett, T
Savage, D
Antman, K
Hesdorffer, CS
Balmaceda, C
Citation: L. Vahdat et al., Reduction of paclitaxel-induced peripheral neuropathy with glutamine, CLIN CANC R, 7(5), 2001, pp. 1192-1197
Authors:
Papadopoulos, KP
Egorin, MJ
Huang, M
Troxel, AB
Kaufman, E
Balmaceda, CM
Vahdat, LT
Hesdorffer, CS
Citation: Kp. Papadopoulos et al., The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m(2) continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer, CANC CHEMOT, 47(1), 2001, pp. 45-50
Citation: J. Lin et al., Membranous glomerulopathy associated with graft-versus-host disease following allogeneic stem cell transplantation - Report of 2 cases and review of the literature, AM J NEPHR, 21(5), 2001, pp. 351-356
Authors:
Moschella, F
Maffei, A
Catanzaro, RP
Papadopoulos, KP
Skerrett, D
Hesdorffer, CS
Harris, PE
Citation: F. Moschella et al., Transcript profiling of human dendritic cells maturation-induced under defined culture conditions: comparison of the effects of tumour necrosis factor alpha, soluble CD40 ligand trimer and interferon gamma, BR J HAEM, 114(2), 2001, pp. 444-457
Authors:
Papadopoulos, KP
Ayello, J
Reiss, RF
Troxel, A
Kaufman, E
Vahdat, LT
Antman, KH
Hesdorffer, CS
Citation: Kp. Papadopoulos et al., CD34(+) cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer, J HEMATH ST, 8(4), 1999, pp. 357-363
Authors:
Papadopoulos, KP
Hesdorffer, CS
Suciu-Foca, N
Hibshoosh, H
Harris, PE
Citation: Kp. Papadopoulos et al., Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human breast carcinoma cells, CLIN CANC R, 5(8), 1999, pp. 2089-2093
Authors:
Papadopoulos, KP
Balmaceda, C
Fetell, M
Kaufman, E
Vahdat, LT
Bruce, J
Sisti, M
Isaacson, S
De LaPaz, R
Savage, DG
Troxel, A
Antman, KH
Hesdorffer, CS
Citation: Kp. Papadopoulos et al., A phase I study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumors, J NEURO-ONC, 44(2), 1999, pp. 155-162